How does rifampicin affect linagliptin exposure and activity?

Repeated co-administration of rifampicin with 5 mg linagliptin decreased linagliptin steady-state AUC by 39.6%, Cmax by 43.8%, and trough DPP‑4 inhibition by about 30%, so full efficacy may not be achieved, particularly with long-term use.